Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long?
Department of Internal Medicine, Yale School of Medicine, New Haven, Conn.
Sara
S
Barmettler
Section of Allergy and Clinical Immunology, Yale School of Medicine, New Haven, Conn. Electronic address: christina.price@yale.edu.
Christina
C
Price
D000293:Adolescent; D000328:Adult; D000361:Agammaglobulinemia / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D000368:Aged; D001402:B-Lymphocytes / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D017578:Immunoglobulin Class Switching; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007156:Immunologic Memory; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
D016756:Immunoglobulins, Intravenous; D000069283:Rituximab